Role of radiopharmaceuticals in the diagnosis and treatment of neuroendocrine tumours.
Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria.
Irene J
IJ
Virgolini
Michael
M
Gabriel
Elisabeth
E
von Guggenberg
Daniel
D
Putzer
Dorota
D
Kendler
Clemens
C
Decristoforo
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018450:Disease Progression; D005544:Forecasting; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007676:Kidney Failure, Chronic / Q000139:chemically induced; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy; D018579:Patient Selection; D010455:Peptides; D049268:Positron-Emission Tomography / Q000379:methods; D011788:Quality of Life; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D018000:Receptors, Peptide / Q000037:antagonists & inhibitors / Q000528:radiation effects; D017481:Receptors, Somatostatin / Q000037:antagonists & inhibitors / Q000528:radiation effects; D016896:Treatment Outcome
D010455:Peptides; D019275:Radiopharmaceuticals; D018000:Receptors, Peptide; D017481:Receptors, Somatostatin